Clinical Implications of High MET Gene Dosage in Non-Small Cell Lung Cancer Patients without Previous Tyrosine Kinase Inhibitor Treatment

Cooper, 1984, Molecular cloning of a new transforming gene from a chemically transformed human cell line, Nature, 311, 29, 10.1038/311029a0 Bottaro, 1991, Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product, Science, 251, 802, 10.1126/science.1846706 Birchmeier, 2003, Met, metastasis, motility and more, Nat Rev Mol Cell Biol, 4, 915, 10.1038/nrm1261 Maulik, 2002, Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition, Cytokine Growth Factor Rev, 13, 41, 10.1016/S1359-6101(01)00029-6 Corso, 2008, Silencing the MET oncogene leads to regression of experimental tumors and metastases, Oncogene, 27, 684, 10.1038/sj.onc.1210697 Ichimura, 1996, Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance, Jpn J Cancer Res, 87, 1063, 10.1111/j.1349-7006.1996.tb03111.x Tsao, 1998, Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers, Lung Cancer, 20, 1, 10.1016/S0169-5002(98)00007-5 Masuya, 2004, The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients, Br J Cancer, 90, 1555, 10.1038/sj.bjc.6601718 Schmidt, 1997, Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas, Nat Genet, 16, 68, 10.1038/ng0597-68 Ma, 2003, c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions, Cancer Res, 63, 6272 Kong-Beltran, 2006, Somatic mutations lead to an oncogenic deletion of met in lung cancer, Cancer Res, 66, 283, 10.1158/0008-5472.CAN-05-2749 Krishnaswamy, 2009, Ethnic differences and functional analysis of MET mutations in lung cancer, Clin Cancer Res, 15, 5714, 10.1158/1078-0432.CCR-09-0070 Kuniyasu, 1992, Frequent amplification of the c-met gene in scirrhous type stomach cancer, Biochem Biophys Res Commun, 189, 227, 10.1016/0006-291X(92)91548-5 Hara, 1998, Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization, Lab Invest, 78, 1143 Miller, 2006, Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma, Oncogene, 25, 409, 10.1038/sj.onc.1209057 Zhao, 2005, Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis, Cancer Res, 65, 5561, 10.1158/0008-5472.CAN-04-4603 Engelman, 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science, 316, 1039, 10.1126/science.1141478 Bean, 2007, MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib, Proc Natl Acad Sci U S A, 104, 20932, 10.1073/pnas.0710370104 Cappuzzo, 2009, MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients, Ann Oncol, 20, 298, 10.1093/annonc/mdn635 Onozato, 2009, Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers, J Thoracic Oncol, 4, 5, 10.1097/JTO.0b013e3181913e0e Kubo, 2009, MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors, Int J Cancer, 124, 1778, 10.1002/ijc.24150 Cappuzzo, 2009, Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients, J Clin Oncol, 27, 1667, 10.1200/JCO.2008.19.1635 Chen, 2009, Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer, Pathol Oncol Res, 4, 651, 10.1007/s12253-009-9167-8 Beau-Faller, 2008, MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort, J Thorac Oncol, 3, 331, 10.1097/JTO.0b013e318168d9d4 Huang, 2004, High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan, Clin Cancer Res, 10, 8195, 10.1158/1078-0432.CCR-04-1245 Livak, 2001, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method, Methods, 25, 402, 10.1006/meth.2001.1262 Wu, 2008, Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of lung in Taiwan and its implication, Cancer, 113, 3199, 10.1002/cncr.23925 Chang, 2008, Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients, Lung Cancer, 61, 328, 10.1016/j.lungcan.2008.01.009 Liu, 2010, Prognostic implications of EGFR and KRAS gene mutations, and EGFR gene copy numbers in surgically resectable non-small cell lung cancer patients in Taiwan, J Thorac Oncol, 5, 1175, 10.1097/JTO.0b013e3181e2f4d6